---
title: Why Longevity Drugs Now Target 5 Pathways Instead of One Disease
slug: "caloric-restriction-mimetics-2025-review"
description: 2025 review highlights shift toward geroprotectors targeting AMPK, mTOR,
  and autophagy pathways
date: '2026-02-17'
category: Research
featured: false
author: Longevity Leak Research Team
study_url: https://link.springer.com/article/10.1007/s10522-025-10269-0
published: true
---
# Why Longevity Drugs Now Target 5 Pathways Instead of One Disease

## What the 2025 Review Is Saying

The core message is straightforward: aging biology is multi-system, so single-target drugs often underdeliver. The review maps five recurring intervention domains in the current longevity pipeline, including nutrient-sensing (mTOR, AMPK), mitochondrial resilience, inflammation control, and autophagy support.

Instead of asking "does this compound cure one disease?" the field is increasingly asking "does this intervention shift several aging-risk pathways at once?"

## Why This Matters for Real Users

For most adults, the strongest baseline interventions are still non-pharmacologic: exercise, sleep regularity, blood-pressure control, and metabolic health. Drug candidates are best viewed as potential amplifiers of a strong foundation, not replacements for it.

If you are tracking longevity options, it helps to organize decisions by pathway and risk profile, not by hype cycle. In this framework, compounds like [Rapamycin](/supplements/rapamycin), [Berberine](/supplements/berberine), and [NMN](/supplements/nmn) sit in different evidence and safety zones.

## Practical Takeaway

The "best" protocol is rarely one molecule. A cleaner strategy is layered:

- lifestyle pillars first
- targeted biomarker tracking
- conservative add-ons matched to risk tolerance
- regular reassessment as evidence changes

That model is slower, but it is usually safer and more durable.

## Evidence Limits and What We Still Need

Most geroprotective compounds still rely on biomarker and short-to-mid-term outcomes, not hard longevity endpoints. Human trials are often limited by sample size, duration, and heterogeneous dosing schedules. Long-term safety, interaction effects in multi-compound stacks, and subgroup response patterns remain uncertain.

## Sources

1. [Biogerontology 2025 review](https://link.springer.com/article/10.1007/s10522-025-10269-0)
2. [Rapamycin human trial context (PubMed)](https://pubmed.ncbi.nlm.nih.gov/39409408/)
